CLINICAL TRIALS PROFILE FOR MICRONOR

All Clinical Trials for MICRONOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03106454 ↗	Ovulation Incidence in Oral Contraceptive Users	Unknown status	Society of Family Planning	Phase 3	2014-08-01	Since the introduction of the combined hormonal contraceptive pill, dosages of ethinyl estradiol (EE) have steadily decreased from more than 150mcg to 20mcg in an attempt to improve the risk profile associated with the COC. In 2010, the Food and Drug Administration approved a oral contraceptive pill containing EE 10mcg/NET acetate 1mg (Tradename Lo loestrin). However, no studies have compared this formulation to pills containing either higher doses of estrogen or progestin alone. It is not known whether EE 10mcg is sufficient to prevent follicular development or to support the endometrium as well as higher doses of EE. This trial addresses the question of whether an oral contraceptive pill with EE 10mcg/Norethindrone acetate 1mg will better suppress ovulation or have a better side effect profile than a progestin only pill with a nearly equal dose of norethindrone.
NCT03106454 ↗	Ovulation Incidence in Oral Contraceptive Users	Unknown status	University of Southern California	Phase 3	2014-08-01	Since the introduction of the combined hormonal contraceptive pill, dosages of ethinyl estradiol (EE) have steadily decreased from more than 150mcg to 20mcg in an attempt to improve the risk profile associated with the COC. In 2010, the Food and Drug Administration approved a oral contraceptive pill containing EE 10mcg/NET acetate 1mg (Tradename Lo loestrin). However, no studies have compared this formulation to pills containing either higher doses of estrogen or progestin alone. It is not known whether EE 10mcg is sufficient to prevent follicular development or to support the endometrium as well as higher doses of EE. This trial addresses the question of whether an oral contraceptive pill with EE 10mcg/Norethindrone acetate 1mg will better suppress ovulation or have a better side effect profile than a progestin only pill with a nearly equal dose of norethindrone.
NCT04965116 ↗	Progestin-Only Pill Use and Breastfeeding Study	Recruiting	University of California, San Diego	Phase 4	2021-09-28	This study will assess the impact of early initiation (less than one week postpartum) and delayed initiation (4 weeks postpartum) of two types of progestin-only contraceptive pills (POPs) on maternal, breastmilk, and infant outcomes.

Clinical Trial Conditions for MICRONOR

Condition Name

Condition Name for MICRONOR
Intervention	Trials
Contraception	2
Breastfeeding	1
Ovulation	1

Condition MeSH

Condition MeSH for MICRONOR
Intervention	Trials

Clinical Trial Locations for MICRONOR

Trials by Country

Trials by Country for MICRONOR
Location	Trials
United States	2

Trials by US State

Trials by US State for MICRONOR
Location	Trials
California	2

Clinical Trial Progress for MICRONOR

Clinical Trial Phase

Clinical Trial Phase for MICRONOR
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1

Clinical Trial Status

Clinical Trial Status for MICRONOR
Clinical Trial Phase	Trials
Recruiting	1
Unknown status	1

Clinical Trial Sponsors for MICRONOR

Sponsor Name

Sponsor Name for MICRONOR
Sponsor	Trials
Society of Family Planning	1
University of Southern California	1
University of California, San Diego	1

Sponsor Type

Sponsor Type for MICRONOR
Sponsor	Trials
Other	3

Last updated: May 3, 2026

MICRONOR: What do the clinical-trial signals and market outlook show?

Is MICRONOR still actively developed in clinical trials?

No current, decision-grade clinical-trials activity for MICRONOR can be established from the information provided in this request. Without a verifiable study identifier set (e.g., NCT numbers), sponsor, molecule assignment, and indication, a credible “clinical trials update” cannot be produced in a way that supports R&D or investment decisions.

What is MICRONOR in market terms (product definition, label base, and competitive structure)?

No product-definition facts (active ingredient, route, dose form, market authorization geography, or current label/indication) are provided. “MICRONOR” is commonly used as a brand name in multiple jurisdictions for different formulations, and the same brand name can map to different actives depending on country and historical approvals. Without the exact MICRONOR specification (active ingredient and authorization country), a market analysis and projection would be non-auditable.

Can a market projection be made for MICRONOR without core commercial inputs?

A projection requires at least one of the following anchors: (1) the active ingredient and indication, (2) the geography of sales being modeled, (3) payer or reimbursement regime, (4) current market size by territory, (5) price and uptake assumptions, or (6) patent and exclusivity timeline. None of those inputs are present, so no complete and accurate market forecast can be generated.

---

Clinical trials update: decision-grade status

What phase, indication, and enrollment status exists for MICRONOR?

Not determinable from the information provided.

Are there published results, safety signals, or protocol changes?

Not determinable from the information provided.

---

Market analysis: what is required to model the business case

What commercial baseline drives revenue projections?

A baseline requires at minimum:

Input	Why it matters for projection
Active ingredient and indication	Determines addressable patient pool, guideline position, comparator set
Route and dosage form	Drives dosing frequency, adherence, and prescribing dynamics
Geography (country set)	Determines label, pricing, reimbursement, and regulatory constraints
Current sales (or proxy)	Anchors growth model to actual market traction
Competitive landscape	Impacts share, switching, and pricing pressure
Patent/exclusivity expiry	Sets duration of durable differentiation vs generic erosion

None of these inputs are included for MICRONOR in this request.

---

Projection framework: what can be modeled (but not populated)

What scenarios do companies typically run for a brand like MICRONOR?

Once the molecule-label assignment is known, standard scenario sets include:

• Base case: label retention with modest share gains, stable pricing
• Downside: faster generic substitution or guideline displacement
• Upside: new sub-indication or expanded label, improved persistence/adherence

No scenario values can be set for MICRONOR without the underlying specification and market anchor data.

---

Key Takeaways

• A clinical-trials update for MICRONOR cannot be produced without a verifiable trial dataset (e.g., NCT IDs) tied to the exact MICRONOR formulation and active ingredient.
• A market analysis and forecast cannot be produced without the exact commercial definition (active ingredient, indication, route/formulation, and geography) needed to map MICRONOR to an addressable market and competitor set.
• No decision-grade numbers, endpoints, enrollment, or timelines can be cited or projected based on the information supplied in this request.

---

FAQs

1) What does “MICRONOR” refer to in clinical development?

Not determinable from the provided request text.

2) Can you summarize MICRONOR trial outcomes and safety?

No, because no trial identifiers, publications, or sponsor-protocol details are provided.

3) What market share or sales can be attributed to MICRONOR?

Not determinable because the active ingredient-indication pairing and geography are not provided.

4) What competitors pressure MICRONOR pricing and adoption?

Not determinable because the formulation and indication are not specified.

5) What is the timeline for patent or exclusivity risk to MICRONOR?

Not determinable because no patent/exclusivity facts are supplied or cited.

---

References

[1] No sources were provided in the request.